Influence of Food on the Pharmacokinetics of Rabeprazole After Oral Administration of 50-mg Rabeprazole Extended-Release Capsules to Healthy Volunteers

lasting >5 min showed a monotonic decline with increasing dose: placebo 3.8, naronapride 12 mg 2.9, naronapride 40 mg 2.1. The difference between placebo and naronapride 40 mg was significant (p=0.0007), as was the dose-response (p=0.0049). The mean duration of acid reflux episodes also showed some reduction with treatment: 0.67 min on placebo; 0.60 min on both naronapride 12 mg and 40 mg. The dose response was significant (p= 0.0057). Conclusions: Treatment with naronapride resulted in a consistent and dose-related decrease in several measures of esophageal acid exposure, including mean % of time with pH<4.0, total number of acid reflux episodes, the mean duration of acid reflux episodes and the number of acid reflux episodes over 5 min duration. Taken together, these findings suggest that naronapride may be effective in the treatment of acid reflux disorders, and further studies are warranted.